Naureen Quibria

Stock Analyst at Capital One

(n/a)

# 4,476

Out of 4,876 analysts

9

Total ratings

11.11%

Success rate

-44.86%

Average return

Main Sectors:

Top Industries:

Stocks Rated by Naureen Quibria

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	BMEA Biomea Fusion	Initiates: Overweight	$25	$1.99	+1,156.28%	1	Aug 29, 2024
	IMMP Immutep	Initiates: Overweight	$10	$1.63	+513.50%	1	May 17, 2024
	ERAS Erasca	Initiates: Overweight	$8	$1.26	+534.92%	1	Mar 11, 2024
	CARM Carisma Therapeutics	Initiates: Overweight	$10	$0.41	+2,360.63%	1	Oct 3, 2023
	IMCR Immunocore Holdings	Initiates: Overweight	$84	$32.02	+162.34%	1	Aug 16, 2023
	DAWN Day One Biopharmaceuticals	Initiates: Overweight	$40	$6.48	+517.28%	1	Feb 8, 2023
	FENC Fennec Pharmaceuticals	Initiates: Overweight	$11	$8.26	+33.17%	1	Sep 7, 2022
	GNTA Genenta Science	Initiates: Buy	$21	$3.05	+589.66%	1	Jan 13, 2022
	KZIA Kazia Therapeutics	Initiates: Buy	$900	$6.53	+13,682.54%	1	Oct 14, 2021

Biomea Fusion

Aug 29, 2024

Initiates: Overweight

Price Target: $25

Current: $1.99

Upside: +1,156.28%

Immutep

May 17, 2024

Initiates: Overweight

Price Target: $10

Current: $1.63

Upside: +513.50%

Erasca

Mar 11, 2024

Initiates: Overweight

Price Target: $8

Current: $1.26

Upside: +534.92%

Carisma Therapeutics

Oct 3, 2023

Initiates: Overweight

Price Target: $10

Current: $0.41

Upside: +2,360.63%

Immunocore Holdings

Aug 16, 2023

Initiates: Overweight

Price Target: $84

Current: $32.02

Upside: +162.34%

Day One Biopharmaceuticals

Feb 8, 2023

Initiates: Overweight

Price Target: $40

Current: $6.48

Upside: +517.28%

Fennec Pharmaceuticals

Sep 7, 2022

Initiates: Overweight

Price Target: $11

Current: $8.26

Upside: +33.17%

Genenta Science

Jan 13, 2022

Initiates: Buy

Price Target: $21

Current: $3.05

Upside: +589.66%

Kazia Therapeutics

Oct 14, 2021

Initiates: Buy

Price Target: $900

Current: $6.53

Upside: +13,682.54%